Altimmune ALT
NASDAQ ALT
$3.37 +0.13 (+4.18%)
As of: Sep 4, 2026 · 2:24 PM EDT

Altimmune (ALT) Restructuring Costs (2015)

Altimmune (ALT) posted quarterly Restructuring Costs of $26886.0 for Q4 2015, down 93.64% quarter-over-quarter from $422482.0 in Q3 2015.

Analysis

Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends

Altimmune (ALT) has reported Restructuring Costs for 1 consecutive years, with $26886.0 the latest figure, recorded in Q4 2015.

  • In Q4 2015, Restructuring Costs changed N/A year-over-year to $26886.0; the TTM figure through Sep 2016 stood at $26886.0 (changed N/A YoY), while the FY2015 annual figure was $2.5 million, changed N/A from the prior year.
  • Restructuring Costs declined to $26886.0 in Q4 2015 per ALT's latest filing, from $422482.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $2.1 million in Q1 2015 and bottomed at $26886.0 in Q4 2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.87 Bn 131.01 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.57 Bn 77.57 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.19 Bn 53.05 Bn 52.00 Mn
5 Revolution Medicines 44.07 Bn 44.07 Bn -
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.38 Bn 32.07 Bn 992.69 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn -
9 Insmed 27.41 Bn 26.25 Bn 358.27 Mn
10 Altimmune 625.87 Mn 625.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 26,886.00
Sep 30, 2015 422,482.00
Jun 30, 2015 35,982.00
Mar 31, 2015 2.06 Mn